Brendan Smith and Sean Lee's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • Q2 2025
Question
Brendan from Cowen and Sean from Morgan Stanley inquired about the upcoming FAP data, asking what would constitute a successful readout and if the polyp reduction seen to date could support regulatory approval.
Answer
Chief R&D and Commercial Officer Najat Khan noted that with no approved therapeutics for FAP and off-label drugs showing 20-30% polyp reduction, Recursion is looking for a meaningful improvement. She stated that while initial data is promising, the company will await data from a broader patient population later this year before having substantive conversations with regulators about the path to approval.